Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Deep learning in fetal, infant, and toddler neuroimaging research

Chin JH, Wyburd MK, Ayzenberg V, Bayet L, Bilgic B, Chen EM, Chen Y, Dineen Á, Fujita S, Liu J, Jun Y, Camacho MC, Zöllei[...]

AI-CVD-AF: A Novel Atrial Fibrillation Prediction Model Based on Coronary Artery Calcium Scans

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Fan[...]

Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

Friedrich NA, Luu M, Gale R, Chaplin A, Polineni R, Shiang A, Shin D, Freedland SJ, Spiegel B, Ballas LK, Kokorowski P, Daskivich TJ. Are[...]